European nod for Bavencio in first-line bladder cancer

25 January 2021

Germany’s Merck KGaA (MRK: DE) and New York-based Pfizer (NYSE: PFE) have secured a new European approval for the checkpoint blocker Bavencio (avelumab), in bladder cancer.

The decision covers use of the immuno-oncology product as monotherapy for the first-line maintenance treatment of adults with locally advanced or metastatic urothelial carcinoma (UC), after chemotherapy.

The decision is based on results from the JAVELIN Bladder 100 trial, which showed a significant improvement in median overall survival (OS) for the treatment group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK